Adnan Tanovı́c

441 total citations
19 papers, 352 citations indexed

About

Adnan Tanovı́c is a scholar working on Pulmonary and Respiratory Medicine, Reproductive Medicine and Oncology. According to data from OpenAlex, Adnan Tanovı́c has authored 19 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Reproductive Medicine and 5 papers in Oncology. Recurrent topics in Adnan Tanovı́c's work include Sarcoma Diagnosis and Treatment (9 papers), Ovarian cancer diagnosis and treatment (6 papers) and Cancer therapeutics and mechanisms (3 papers). Adnan Tanovı́c is often cited by papers focused on Sarcoma Diagnosis and Treatment (9 papers), Ovarian cancer diagnosis and treatment (6 papers) and Cancer therapeutics and mechanisms (3 papers). Adnan Tanovı́c collaborates with scholars based in Spain, United States and United Kingdom. Adnan Tanovı́c's co-authors include Marcel Jiménez, E. Fernández, Vicente Alfaro, Antonio Nieto, Bradley J. Monk, Luis Paz‐Ares, José Luís Zamora Manzano, Jordi Rubió‐Casadevall, Arrate Plazaola and Salvador Martín‐Algarra and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Adnan Tanovı́c

18 papers receiving 345 citations

Peers

Adnan Tanovı́c
Sunyi Lee South Korea
Angela Ragone Italy
Xiaofang Guo China
Yangyang Yao China
Tomohisa Ishida Japan
Ziv Radisavljevic United States
Suyu Chen China
Huiyan Niu China
Xiaoming Ye China
Wei Ren China
Sunyi Lee South Korea
Adnan Tanovı́c
Citations per year, relative to Adnan Tanovı́c Adnan Tanovı́c (= 1×) peers Sunyi Lee

Countries citing papers authored by Adnan Tanovı́c

Since Specialization
Citations

This map shows the geographic impact of Adnan Tanovı́c's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adnan Tanovı́c with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adnan Tanovı́c more than expected).

Fields of papers citing papers by Adnan Tanovı́c

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adnan Tanovı́c. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adnan Tanovı́c. The network helps show where Adnan Tanovı́c may publish in the future.

Co-authorship network of co-authors of Adnan Tanovı́c

This figure shows the co-authorship network connecting the top 25 collaborators of Adnan Tanovı́c. A scholar is included among the top collaborators of Adnan Tanovı́c based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adnan Tanovı́c. Adnan Tanovı́c is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Monk, Bradley J., et al.. (2020). 830P Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC). Annals of Oncology. 31. S625–S625. 1 indexed citations
2.
Monk, Bradley J., Domenica Lorusso, Antoîne Italiano, et al.. (2016). Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treatment Reviews. 50. 175–182. 32 indexed citations
3.
Kampmann, Eric, Adnan Tanovı́c, Yan Guo, et al.. (2014). Trabectedin Combined with Hyperthermia: Characterization of Enhanced Drug-Efficacy in Human Tumor Cells. Annals of Oncology. 25. iv503–iv503.
4.
Monk, Bradley J., Stanley B. Kaye, Andrés Poveda, et al.. (2013). Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecologic Oncology. 132(1). 176–180. 9 indexed citations
5.
Cesne, Axel Le, Ian Judson, Robert G. Maki, et al.. (2013). Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. British Journal of Cancer. 109(7). 1717–1724. 46 indexed citations
6.
Nieto, Antonio, Adnan Tanovı́c, Bradley J. Monk, et al.. (2013). Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial.. Journal of Clinical Oncology. 31(15_suppl). 5566–5566. 1 indexed citations
7.
Blay, Jean‐Yves, Paolo G. Casali, Antonio Nieto, Adnan Tanovı́c, & Axel Le Cesne. (2013). Efficacy and Safety of Trabectedin as an Early Treatment for Advanced or Metastatic Liposarcoma and Leiomyosarcoma. Future Oncology. 10(1). 59–68. 21 indexed citations
8.
Monk, Bradley J., Heather Dalton, Ivor Benjamin, & Adnan Tanovı́c. (2012). Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer. Current Pharmaceutical Design. 18(25). 3754–3769. 23 indexed citations
9.
10.
Paz‐Ares, Luis, Antonio López–Pousa, Andrés Poveda, et al.. (2010). Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs. 30(2). 729–740. 32 indexed citations
11.
Martín‐Algarra, Salvador, Enrique Espinosa, Jordi Rubió‐Casadevall, et al.. (2009). Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. European Journal of Cancer. 45(5). 732–735. 68 indexed citations
12.
Eisen, Tim, Nick Thatcher, Serge Leyvraz, et al.. (2008). Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer. 64(1). 60–65. 23 indexed citations
13.
Alfaro, Vicente, Martín Cullell-Young, & Adnan Tanovı́c. (2007). Abbreviated Clinical Study Reports with Investigational Medicinal Products for Human Use: Current Guidelines and Recommendations. Croatian Medical Journal. 48(6). 871–877. 7 indexed citations
14.
Tanovı́c, Adnan, E. Fernández, & Marcel Jiménez. (2006). Alterations in intestinal contractility during inflammation are caused by both smooth muscle damage and specific receptor-mediated mechanisms.. PubMed. 47(2). 318–26. 18 indexed citations
15.
16.
Tanovı́c, Adnan & Vicente Alfaro. (2004). Gefitinib: Current status in the treatment of non-small cell lungcancer. Drugs of today. 40(10). 809–809. 6 indexed citations
17.
Tanovı́c, Adnan, Marcel Jiménez, & E. Fernández. (2002). Changes in the inhibitory responses to electrical field stimulation of intestinal smooth muscle from Trichinella spiralis infected rats. Life Sciences. 71(26). 3121–3136. 9 indexed citations
18.
Tanovı́c, Adnan, Marcel Jiménez, & E. Fernández. (2001). Actions of NO donors and endogenous nitrergic transmitter on the longitudinal muscle of rat ileum in vitro. Life Sciences. 69(10). 1143–1154. 18 indexed citations
19.
Tanovı́c, Adnan, Marcel Jiménez, & E. Fernández. (2000). Lack of effect of nitric oxide on KCl, acetylcholine and substance P induced contractions in ileal longitudinal muscle of the rat. Life Sciences. 67(5). 531–541. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sunyi Lee Breakdown of academic impact, for papers by Angela Ragone Breakdown of academic impact, for papers by Xiaofang Guo Breakdown of academic impact, for papers by Yangyang Yao Breakdown of academic impact, for papers by Tomohisa Ishida Breakdown of academic impact, for papers by Ziv Radisavljevic Breakdown of academic impact, for papers by Suyu Chen Breakdown of academic impact, for papers by Huiyan Niu Breakdown of academic impact, for papers by Xiaoming Ye Breakdown of academic impact, for papers by Wei Ren
Rankless by CCL
2026